Home
/
FATE THERAPEUTICS INC
/
Financials
/
Quarterly
FATE THERAPEUTICS INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that FATE THERAPEUTICS INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$1.74M
Nov 13, 2025
Q2
2025
Jun 30, 2025
$1.91M
Aug 12, 2025
Q1
2025
Mar 31, 2025
$1.63M
May 13, 2025
Q3
2025
Sep 30, 2024
$3.07M
Nov 13, 2025
Q2
2025
Jun 30, 2024
$6.77M
Aug 12, 2025
Q1
2025
Mar 31, 2024
$1.93M
May 13, 2025
Q3
2024
Sep 30, 2023
$1.94M
Nov 12, 2024
Q2
2024
Jun 30, 2023
$933.0K
Aug 13, 2024
Q1
2024
Mar 31, 2023
$58.98M
May 9, 2024
Q3
2023
Sep 30, 2022
$14.98M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$18.55M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$18.41M
May 3, 2023
Q3
2022
Sep 30, 2021
$14.23M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$13.41M
Aug 3, 2022
Q1
2022
Mar 31, 2021
$11.14M
May 4, 2022
Q3
2021
Sep 30, 2020
$7.56M
Nov 4, 2021
Q2
2021
Jun 30, 2020
$5.47M
Aug 4, 2021
Q1
2021
Mar 31, 2020
$2.52M
May 5, 2021
Q3
2020
Sep 30, 2019
$2.43M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$2.82M
Aug 5, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2014
Mar 31, 2014
$5.01M
May 13, 2014
Q3
2014
Sep 30, 2013
$209.0K
Nov 12, 2014
Q2
2014
Jun 30, 2013
$290.0K
Aug 12, 2014
Q1
2014
Mar 31, 2013
$472.0K
May 13, 2014
Q3
2013
Sep 30, 2012
$528.0K
Nov 13, 2013
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($32.25M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($34.07M)
Aug 12, 2025
Q3
2025
Jun 30, 2025
($34.07M)
Nov 13, 2025
Q2
2025
Mar 31, 2025
($37.62M)
Aug 12, 2025
Q3
2025
Mar 31, 2025
($37.62M)
Nov 13, 2025
Q1
2025
Mar 31, 2025
($37.62M)
May 13, 2025
Q3
2025
Sep 30, 2024
($47.68M)
Nov 13, 2025
Q3
2025
Jun 30, 2024
($38.43M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($38.43M)
Aug 12, 2025
Q3
2025
Mar 31, 2024
($48.00M)
Nov 13, 2025
Q2
2025
Mar 31, 2024
($48.00M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($48.00M)
May 13, 2025
Q3
2024
Sep 30, 2023
($45.17M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($52.76M)
Aug 13, 2024
Q3
2024
Jun 30, 2023
($52.76M)
Nov 12, 2024
Q2
2024
Mar 31, 2023
($18.88M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($18.88M)
May 9, 2024
Q3
2024
Mar 31, 2023
($18.88M)
Nov 12, 2024
Q3
2023
Sep 30, 2022
($83.56M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($76.11M)
Aug 8, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($34.74M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($36.97M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($41.28M)
May 13, 2025
Q3
2025
Sep 30, 2024
($52.38M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($45.08M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($51.07M)
May 13, 2025
Q3
2024
Sep 30, 2023
($51.28M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($62.57M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($28.59M)
May 9, 2024
Q3
2023
Sep 30, 2022
($86.39M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($83.11M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($74.47M)
May 3, 2023
Q3
2022
Sep 30, 2021
($54.62M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($46.78M)
Aug 3, 2022
Q1
2022
Mar 31, 2021
($46.21M)
May 4, 2022
Q3
2021
Sep 30, 2020
($31.49M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($28.71M)
Aug 4, 2021
Q1
2021
Mar 31, 2020
($34.49M)
May 5, 2021
Q3
2020
Sep 30, 2019
($27.12M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($24.08M)
Aug 5, 2020